Today: 22 May 2026
Why Procter & Gamble stock is edging up today after earnings and new analyst upgrades
23 January 2026
2 mins read

Why Procter & Gamble stock is edging up today after earnings and new analyst upgrades

New York, January 23, 2026, 11:01 EST — Regular session

  • Procter & Gamble shares edged up roughly 0.2% in late morning trading, after climbing nearly 3% the previous day.
  • A quarterly revenue miss and declining U.S. volumes kept demand under scrutiny, despite profits beating estimates.
  • JPMorgan and Wells Fargo raised their targets, shifting focus to U.S. volumes and the policy outlook due next week.

Procter & Gamble shares edged up roughly 0.2% to $150.28 in late morning trading Friday in New York, after a higher open and a short-lived peak at $151.63.

The modest uptick keeps attention on this defensive heavyweight, a key barometer for everyday U.S. spending. P&G has been working to return to more consistent growth.

This week’s focus shifts from price to volume. P&G can hold onto margins for now if consumers keep trading down or postponing buys, but the company risks losing market share in the process.

The stock rose roughly 2.7% on Thursday, standing out as one of the top contributors to the Dow’s gain, MarketWatch data shows.

P&G’s fiscal second-quarter net sales edged up about 1% to $22.21 billion, falling just short of analysts’ consensus of $22.28 billion. Adjusted earnings came in at $1.88 a share, beating estimates. Reuters noted the sales miss was linked to softer demand in the U.S. and government shutdown-related disruptions. Finance chief Andre Schulten said volumes declined 1%, adding, “We need to get the U.S. growing.” Brian Mulberry of Zacks Investment Management pointed to consumers making cost-driven choices, while David Wagner at Aptus Capital Advisors commented the market “can look past the organic sales miss.” Reuters

Procter & Gamble reported fiscal second-quarter net sales of $22.2 billion, up 1% from a year earlier. Organic sales, which exclude currency effects and acquisitions or divestitures, held steady as a 1% gain from higher pricing was offset by a 1% drop in unit volume. CEO Shailesh Jejurikar said the results “keep us on track to deliver within our fiscal year guidance ranges.” The company also returned $4.8 billion to shareholders via dividends and buybacks during the quarter. Procter & Gamble

The company cut its fiscal 2026 diluted earnings growth forecast to 1% to 6%, pointing to higher non-core restructuring charges. It maintained its core EPS growth outlook at in-line to up 4%, with a core EPS range of $6.83 to $7.09. Tariff costs are projected at about $400 million after tax for fiscal 2026, while currency effects are expected to boost results by roughly $200 million after tax.

A separate SEC filing revealed that P&G provided slides cited during the earnings conference call.

Analyst updates came fast on Friday. JPMorgan bumped P&G to Overweight from Neutral, lifting its price target to $165 from $157. The firm pointed to the company’s potential to speed up organic sales growth and boost margins, highlighting management’s confidence that they are “on the right track.” TipRanks

Wells Fargo bumped its price target to $165 from $158, maintaining its Overweight rating, but pointed to a recurring issue: U.S. trends. The firm said the question remains whether “if improves” will play out. TipRanks

Household and staples stocks showed a mixed picture: Colgate-Palmolive gained roughly 0.5%, Unilever climbed about 0.7%, while Kimberly-Clark dipped nearly 0.3%.

The risk is clear. Should U.S. volumes continue to fall and promotional activity increase, P&G might need to boost spending to protect shelf space. That comes on top of mounting pressure from tariffs and restructuring costs weighing on the gap between “core” and reported profit.

Investors are now focused on signs that U.S. demand might be stabilizing, while also eyeing the Federal Reserve’s meeting on January 27–28. That gathering could shift expectations for interest rates and set the mood for defensive stocks.

Stock Market Today

  • Cybersecurity Stocks Outperform Semiconductors, Hit Record Highs in May
    May 22, 2026, 10:09 AM EDT. Cybersecurity stocks are leading the tech sector rally in May, with the First Trust Nasdaq Cybersecurity ETF (CIBR) surging over 20%, surpassing the iShares Semiconductor ETF (SOXX) and iShares Expanded Tech-Software Sector ETF (IGV). CIBR set six consecutive intraday records, reflecting strong investor interest despite recent market volatility. While semiconductors remain a critical component of the bull market, up nearly 75% this year, cybersecurity shows renewed leadership, blending software, cloud, AI infrastructure, and enterprise spending. Key players like CrowdStrike, Palo Alto Networks, Datadog, Fortinet, and Cisco have significantly added to their market caps. Sustaining above the $78 breakout point is crucial for continued cyber sector strength; falling below may signal a tech rally pause.

Latest articles

Archer Aviation Rises as Air-Taxi Hopes Return

Archer Aviation Rises as Air-Taxi Hopes Return

22 May 2026
Archer Aviation stock traded at $6.14 in premarket Friday after jumping 5.8% Thursday on heavy volume, as investors watched FAA certification progress for its Midnight eVTOL aircraft. Archer reported a Q1 net loss of $217.7 million and ended March with $1.78 billion in cash. The company expects initial U.S. operations in 2026 under a federal pilot program. S&P 500 and Nasdaq futures were higher before the open.
UP Fintech Shares Drop in Premarket After Crackdown on Tiger Brokers in China

UP Fintech Shares Drop in Premarket After Crackdown on Tiger Brokers in China

22 May 2026
UP Fintech’s Nasdaq-listed shares fell 34.47% to $3.83 in premarket trading after China’s securities regulator said its Tiger Brokers unit, Futu, and Longbridge operated unlicensed cross-border securities businesses for mainland investors. The regulator plans to confiscate illegal gains and impose penalties. UP Fintech is set to report first-quarter results on June 2.
Akari Therapeutics Shares Jump As KRAS Cancer News Returns

Akari Therapeutics Shares Jump As KRAS Cancer News Returns

22 May 2026
Akari Therapeutics shares more than doubled in premarket trading Friday after its lead cancer drug showed positive preclinical results in KRAS-mutated pancreatic cancer models and the company announced a $5.5 million private placement. The stock was quoted at $10.15, up from Thursday’s $5.14 close. Akari plans to start Phase 1 human trials of AKTX-101 by mid-2027. The company reported $2.8 million in cash at March 31.
Walmart stock ticks higher as PhonePe IPO share-sale details emerge — what’s next for WMT
Previous Story

Walmart stock ticks higher as PhonePe IPO share-sale details emerge — what’s next for WMT

Plug Power stock price today: PLUG steadies near $2.60 as share-vote clock ticks and Galp project update lands
Next Story

Plug Power stock price today: PLUG steadies near $2.60 as share-vote clock ticks and Galp project update lands

Go toTop